Inhibition of 6-Phosphofructo-2-kinase (PFKFB3) Suppresses Glucose Metabolism and the Growth of HER2+ Breast Cancer

Data from a recent clinical trial support the potential clinical utility of PFKFB3 inhibitors as chemotherapeutic agents against HER2+ breast cancer.

 Breast Cancer Research and Treatment

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.